Variable | Category | Total | Repeatedly measured |
---|---|---|---|
Baseline measurement | |||
 n |  | 43 | 31 |
 Tumor mutation burden (mutations/mb) |  | 5.4 (3.3–6.7) | 4.9 (3.3–6.7) |
 KRAS mutation type in tumor | G12D | 22 (51.2) | 16 (51.6) |
 | G12V | 11 (25.6) | 7 (22.6) |
 | Others | 5 (11.6) | 3 (9.7) |
 | Not mutated | 5 (11.6) | 5 (16.1) |
 KRAS mutation in tumor | Yes | 38 (88.4) | 26 (83.9) |
 KRAS mutation abundance in tumor (%)a |  | 25.8 (12.5–34.4) | 23.9 (10.5–36.4) |
 KRAS mutation abundance in tumor ≥ 30.0% | Yes | 15 (34.9) | 10 (32.3) |
 KRAS mutation in blood | Yes | 32 (74.4) | 23 (74.2) |
 KRAS mutation abundance in blood (%)aa |  | 5.8 (1.5–16.7) | 4.7 (1.4–13.6) |
 KRAS mutation abundance in blood ≥ 5.0% | Yes | 16 (37.2) | 11 (35.5) |
 TP53 mutation in tumor | Yes | 30 (69.8) | 20 (64.5) |
 TP53 mutation abundance in tumor (%)a |  | 30.8 (15.0–47.7) | 30.2 (16.0–51.1) |
 TP53 mutation abundance in tumor ≥ 30.0% | Yes | 16 (37.2) | 10 (32.3) |
 TP53 mutation in blood | Yes | 27 (62.8) | 19 (61.3) |
 TP53 mutation abundance in blood (%)a |  | 7.2 (1.8–12.7) | 3.2 (1.9–10.2) |
 TP53 mutation abundance in blood ≥ 5.0% | Yes | 14 (32.6) | 9 (29.0) |
 CDKN2A mutation in tumor | Yes | 9 (20.9) | 7 (22.6) |
 CDKN2A mutation abundance in tumor (%)a |  | 33.4 (20.4–45.9) | 33.4 (2.1–45.9) |
 CDKN2A mutation abundance in tumor ≥ 30.0% | Yes | 5 (11.6) | 4 (12.9) |
 CDKN2A mutation in blood | Yes | 9 (20.9) | 7 (22.6) |
 CDKN2A mutation abundance in blood (%)a |  | 6.6 (1.4–8.3) | 3.2 (1.4–6.8) |
 CDKN2A mutation abundance in blood ≥ 5.0% | Yes | 5 (11.6) | 3 (9.7) |
 SMAD4 mutation in tumor | Yes | 7 (16.3) | 4 (12.9) |
 SMAD4 mutation abundance in tumor (%)a |  | 19.7 (1.7–39.6) | 10.4 (1.2–29.4) |
 SMAD4 mutation abundance in tumor ≥ 30.0% | Yes | 3 (7.0) | 1 (3.2) |
 SMAD4 mutation in blood | Yes | 7 (16.3) | 4 (12.9) |
 SMAD4 mutation abundance in blood (%)a |  | 3.9 (1.5–14.3) | 1.9 (1.2–3.1) |
 SMAD4 mutation abundance in blood ≥ 5.0% | Yes | 3 (7.0) | 0 (0.0) |
 ARID1A mutation in tumor | Yes | 6 (14.0) | 4 (12.9) |
 ARID1A mutation abundance in tumor (%)a |  | 11.7 (2.3–21.8) | 4.4 (2.2–14.1) |
 ARID1A mutation abundance in tumor ≥ 30.0% |  | 1 (2.3) | 0 (0.0) |
 ARID1A mutation in blood | Yes | 4 (9.3) | 2 (6.5) |
 ARID1A mutation abundance in blood (%)a |  | 5.7 (1.2–13.4) | 1.2 (0.2–2.2) |
 ARID1A mutation abundance in blood ≥ 5.0% | Yes | 2 (4.7) | 0 (0.0) |
 BRAF mutation in tumor | Yes | 1 (2.3) | 1 (3.2) |
 BRAF mutation in blood | Yes | 2 (4.7) | 2 (6.5) |
 PI3KCA mutation in tumor | Yes | 2 (4.7) | 1 (3.2) |
 PI3KCA mutation in blood | Yes | 0 (0.0) | 0 (0.0) |
 Number of any mutated genes in tumor |  | 5 (4–7) | 5 (4–7) |
 Number of any mutated genes in blood |  | 3 (2–5) | 4 (2–5) |
 Number of mutated driver genes in tumor |  | 2 (2–3) | 2 (2–3) |
 Number of mutated driver genes in blood |  | 2 (1–3) | 2 (1–3) |
 Germline mutation | Yes | 9 (20.9) | 7 (22.6) |